Literature DB >> 32016027

Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma.

Joan Tymon-Rosario1, Burak Zeybek1, Chanhee Han1, Alessandro D Santin1.   

Abstract

Entities:  

Year:  2019        PMID： 32016027      PMCID： PMC6976388          DOI： 10.21037/atm.2019.10.28

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  17 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Katherine Bell-McGuinn; Carol Aghajanian; Heidi J Gray; Krishnansu S Tewari; Steven C Rubin; Thomas J Rutherford; John K Chan; Alice Chen; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2015-03-24       Impact factor: 5.482

3.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Beth Y Karlan; Toshiyasu Taniguchi; Elena Fountzilas; Nancy Francoeur; Douglas A Levine; Stephen A Cannistra
Journal:  J Clin Oncol       Date:  2010-06-14       Impact factor: 44.544

4.  Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

Authors:  Susan M Domchek; Carol Aghajanian; Ronnie Shapira-Frommer; Rita K Schmutzler; M William Audeh; Michael Friedlander; Judith Balmaña; Gillian Mitchell; Georgeta Fried; Salomon M Stemmer; Ayala Hubert; Ora Rosengarten; Niklas Loman; Jane D Robertson; Helen Mann; Bella Kaufman
Journal:  Gynecol Oncol       Date:  2015-12-23       Impact factor: 5.482

5.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Authors:  Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

6.  PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.

Authors:  Jianfeng Shen; Wei Zhao; Zhenlin Ju; Lulu Wang; Yang Peng; Marilyne Labrie; Timothy A Yap; Gordon B Mills; Guang Peng
Journal:  Cancer Res       Date:  2018-11-27       Impact factor: 12.701

7.  The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

Authors:  Shahneen K Sandhu; William R Schelman; George Wilding; Victor Moreno; Richard D Baird; Susana Miranda; Lucy Hylands; Ruth Riisnaes; Martin Forster; Aurelius Omlin; Nathan Kreischer; Khin Thway; Heidrun Gevensleben; Linda Sun; John Loughney; Manash Chatterjee; Carlo Toniatti; Christopher L Carpenter; Robert Iannone; Stan B Kaye; Johann S de Bono; Robert M Wenham
Journal:  Lancet Oncol       Date:  2013-06-28       Impact factor: 41.316

8.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Authors:  Panagiotis A Konstantinopoulos; Steven Waggoner; Gregory A Vidal; Monica Mita; John W Moroney; Robert Holloway; Linda Van Le; Jasgit C Sachdev; Eloise Chapman-Davis; Gerardo Colon-Otero; Richard T Penson; Ursula A Matulonis; Young Bae Kim; Kathleen N Moore; Elizabeth M Swisher; Anniina Färkkilä; Alan D'Andrea; Erica Stringer-Reasor; Jing Wang; Nathan Buerstatte; Sujata Arora; Julie R Graham; Dmitri Bobilev; Bruce J Dezube; Pamela Munster
Journal:  JAMA Oncol       Date:  2019-08-01       Impact factor: 31.777

9.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

10.  A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.

Authors:  Kaiming Sun; Keith Mikule; Zebin Wang; Grace Poon; Aparajitha Vaidyanathan; Gillian Smith; Zhi-Yi Zhang; Jeffrey Hanke; Sridhar Ramaswamy; Jing Wang
Journal:  Oncotarget       Date:  2018-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.